Corneal Cross-Linking: A Keratoconus Treatment Option

Corneal cross-linking (CXL), which has been performed in Europe since 1997, has now been FDA approved in the United States. However, because it took so many years to acquire FDA approval, the methodology used in this FDA-approved version is now outdated. This method of CXL is called Epi-OFF, where the top skin layer of the cornea is removed as part of the CXL procedure for keratoconus treatment.

The alternative corneal cross-linking method is called Epi-ON or trans-epithelial CXL. With this method, the outer skin layer of the cornea is not removed, which provides many advantages. These advantages include much faster recovery, the ability to have both eyes treated on the same day, less chance of infection and scarring, and much less discomfort during the recovery.

Epi-ON CXL is a relatively non-invasive and low-risk procedure designed to strengthen the corneal tissue of a person’s eye, particularly when keratoconus exists. The goal of CXL for keratoconus treatment is to prevent the corneal tissue from progressively weakening, thereby prolonging or avoiding a riskier and invasive corneal transplant.

Corneal cross-linking can also be used to treat other problems, such as fluctuating vision due to prior Radial Keratotomy (RK) surgery, a procedure that was mostly performed from 1980 to 1995.

DSC05674 EDITED 8 21 19

How is corneal cross-linking performed?

Corneal cross-linking is performed by applying liquid Riboflavin (one of the B vitamins) to the eye to saturate the cornea followed by a specific amount and duration of ultraviolet light. This combination causes strong bonds to form between corneal fibers, providing strength and stability to the tissue. In some cases, in addition to treating keratoconus, it also reduces the amount of astigmatism for vision to improve. This creates more options for vision correction, such as standard soft or toric contact lenses, glasses, and even LASIK.

When will corneal cross-linking be available?

As cornea specialists, Dr. Mozayeni and Dr. Nunnery have been carefully following the development of corneal cross-linking for many years and firmly believes it is in the best interest of patients to undergo the Epi-ON version of this procedure. FDA approval for the Epi-OFF version occurred in the middle of 2016, and is available at some facilities but has since become outdated.

At Providence Eye & Laser Specialists, we intend to offer the safer, more advanced Epi-ON corneal cross-linking procedure to treat diseases like keratoconus in the future and are currently exploring our options to make this available in our community as soon as medically possible.

Schedule an Appointment

Contact us today for a complete examination, including corneal mapping, and get established as a candidate for the exciting corneal cross-linking technology that could save your vision.

Sending... Please complete all required fields

Communication with our office through this website is not for the purpose of asking questions regarding a particular health concern or issue, and neither future patients nor active patients should use this website as a method to gather advice or make Providence Eye & Laser Specialists aware of any medical condition that requires attention. All such communication should be strictly made by telephone. Although we attempt to answer all communication through this website, there is no guarantee it will be electronically delivered in a timely fashion or at all, and we cannot guarantee a response to all submissions.

Thank you for contacting Providence Eye & Laser Specialists!

We are looking forward to assisting you! You will receive a call from one of our team members within 1 business day from our main number (704) 540-9595. We use this number for both phone calls and text messaging. We do not use a call center. Please add this number to your contacts enabling you to recognize us when we reach out to you.

We look forward to getting to know you!

Ready to get started?

Schedule a Free LASIK consultation with Dr. Mozayeni